SEC Form 4 · accession 0001209191-18-037098
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert F Apple
Officer — President & CEO · Director
Period of report
Jun 7, 2018
Accepted (ET)
Jun 11, 2018 · 7:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 7, 2018 | F | 32,031 | $2.70 | D | 1,225,006 | D | |
| Common StockF2 | Jun 8, 2018 | A | 305,556 | $2.70 | A | 1,530,562 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F4 | $2.70 | Jun 8, 2018 | A | 591,510 | A | — | Jun 8, 2028 | Common Stock | 591,510 | 591,510 | D |
Explanation of responses
- F1Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award.
- F2Represents grant of restricted stock units made under the 2008 Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant.
- F3Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan.
- F4The options vest in equal quarterly installments over three years from the date of grant.